This Biotech Has the DNA of a Tech Company

This overlooked biotech has something most others don't: real profits and growth ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

BROUGHT TO YOU BY MANWARD PRESS This Biotech Has a Tech Company's DNA SPONSORED FREE Daily Profits Live 100 x 100% Winner Open House Celebration! Over the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 100 opportunities to DOUBLE their money... Now it's YOUR CHANCE to hunt MASSIVE gains like these with a professional trader for an ENTIRE WEEK... 100% FREE! Last open house he went 23-for-24 with TWO 100% winners during the week... And the time before that, he went 18-for-20, with FOUR 100% winners... Including one that went for 1,129% within just 2 days! Click here to join FREE >>   Alpesh Patel Quantitative Investing Specialist Unicorns may be a myth, but today's stock pick is real. Now, biotech companies aren't for the faint of heart. These stocks are notoriously volatile and hard for the average investor to understand. Lucky for you, my hedge fund and I have a lot of experience in this area. SPONSORED "A juggernaut... to rival the likes of Google and Netflix in power and value" Is this most valuable AI stock in the world?   So when my GVI rating system zeroed in on this biotech gem, I knew I had something special. Not only does the company generate cash AND profits, but it's both a biotech and technology company rolled into one. Tune in to today's Dealmaker's Diary to see what makes this stock so exciting. Don't miss these critical insights... NOW. This is the kind of research my clients pay thousands for... but you get it for FREE as a Total Wealth subscriber. Click here or on the image below to dive in. Happy hunting, Alpesh WATCH THE VIDEO (WITH TRANSCRIPT) SPONSORED Backdoor Gold Play Gold is already over $2,500 an ounce, but one hidden play gives you a stake in more than 1 oz for less than $20. Click here for urgent details on this backdoor gold play.   Want more content like this? YES NO

Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2025 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.